Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

NCT00511095 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
207
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Dynavax Technologies Corporation